Novel HPMC Capsules – Bioequivalence & Functional Performance
Sponsored by: Capsugel
- H P M C
Date: 16 March
Time: 3PM London/11AM New York
Hydroxypropyl methylcellulose (HPMC) capsules are well-vetted and have been used in pharmaceutical formulations for many years. But a new HPMC-polymer capsule (Vcaps® Plus) made through an innovative thermo-gelation process avoids the addition of gelling agents that can react with the pH or ionic strengths of dissolution media, providing gelatin-like performance.
Although HPMC capsules are used in marketed drugs, there are few comparisons of the in-vivo performance between gelatin and HPMC in literature. In this webinar, experts will present the in-vitro dissolution and an in-vivo bioequivalence study comparing the performance of the identical formulation of three different drugs in Vcaps Plus HPMC capsules to hard gelatin capsules.
In addition, we will present data suggesting there may be value in formulating with HPMC in order to increase bioavailability of weakly-basic drugs and of high energy forms of low solubility drugs, such as salts and amorphous solid dispersions (ASDs), by sustaining drug supersaturation in the intestine.
Matt Richardson, Ph.D.,
Manager, Pharmaceutical Business Development, Capsugel
Matt Richardson is the Manager of Pharmaceutical Business Development at Capsugel. He is a graduate of Wofford College, holds a doctorate in Synthetic Organic Chemistry from Wake Forest University and a post-doctoral appointment at Virginia Tech. Before joining Capsugel he was with SchweizerHall and Irix Pharmaceuticals as a process development Scientist for API synthesis.
Since joining Capsugel in 2005, he has worked with many pharmaceutical and nutraceutical customers to understand the formulation aspects of their products with two-piece hard capsules and has been an invited speaker at numerous seminars and webinars on topics of hard capsules, crosslinking, capsules for use in delayed release, as well as DPI-based inhalation.
Michael Morgen, Ph.D.,
Senior Principal Scientist
Michael Morgen is a senior principal scientist at Bend Research, a division of Capsugel Dosage Form Solutions, where he has worked since 2003. He has more than 15 years of experience in the development and evaluation of novel polymeric materials including pharmaceutical formulations for oral and non-oral delivery, particularly for low solubility molecules.
He received a doctorate in physical chemistry from the University of California at Berkeley. He is co-inventor on 14 patents and patent applications and has co-authored 21 papers and book chapters.
Key Learning Objectives
- Characteristics of leading-edge HPMC capsules
- The in-vitro and in-vivo performance comparison of HGC vs. HPMC for several drugs
- Functional performance of HPMC when used with weakly-basic drugs
- Pharmaceutical Drug Developers
- Heads of Research and Development
- Heads of Formulation
- Research Scientists
- Formulation Scientists